Literature DB >> 10924306

Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure.

C Torp-Pedersen, M Moller, L Kober, A J Camm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10924306     DOI： 10.1053/euhj.1999.2049

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  4 in total

Review 1.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

2.  Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure.

Authors:  H-J Schneider; O Husser; M Rihm; S Fredersdorf; C Birner; S Dhein; F Muders; A Jeron; H Goegelein; G A Riegger; A Luchner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-30       Impact factor: 3.000

Review 3.  Prevention of and medical therapy for atrial arrhythmias in heart failure.

Authors:  A U Khand; J G F Cleland; P C Deedwania
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

4.  Drug therapy in atrial fibrillation management: where do we stand in 2010?

Authors:  Gholamreza Davoodi; Mehdi Montazeri
Journal:  J Tehran Heart Cent       Date:  2010-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.